Merck & Co. saw its acquisition discussions with Revolution Medicines fall apart, causing a drop in Revolution's shares and raising concerns about Merck's valuation strategies. With a critical earnings report set for February 3, 2026, analysts predict strong sales fueled by Keytruda despite potential growth challenges in non-oncology sectors. Additionally, recent earnings estimates for 2026 have been revised downward, further intensifying the uncertainty surrounding Merck's growth trajectory.
“Revolution Medicines (RVMD) · tumbled · over 20% · after Merck deal talks collapse”
“Pfizer, AbbVie, Merck & Co., Uber Technologies, and Emerson Electric · are key names from · healthcare and industrials · scheduled to report earnings”
“Merck · is set to report · fourth-quarter and full-year 2025 earnings · Feb. 3, before market open”
“Merck · earnings estimates for 2026 have declined from · per share · $8.50 to $6.54”
“Merck · exceeded earnings expectations in · the trailing four quarters · true”
“Merck · delivered an earnings surprise of · 9.32% · last reported quarter”
“Merck · has an Earnings ESP of · Zacks Rank · +0.33%”
“Merck shares · have risen · 9.4% in the past year · true”
“Merck · trades at · 15.62 forward earnings · lower than 18.18 for the industry”
“Merck · has more than · six blockbuster drugs · true”
“Merck · faces several near-term challenges, including · persistent challenges for Gardasil in China · true”
“Short-term investors · may stay away from · MRK stock · true”
